Skip to content

Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3

Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00732758
Acronym
Vitamin D RCT
Enrollment
157
Registered
2008-08-12
Start date
2008-10-31
Completion date
2011-10-31
Last updated
2015-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Vitamin D Deficiency, Vitamin D Insufficiency, Child, Adolescent, African American, Caucasian, Definition, Preadolescent

Brief summary

The study objective is to characterize the threshold levels of serum 25-hydroxyvitamin D for the definition of vitamin D insufficiency in 8-14 year old African American and Caucasian children. We propose a 6 month randomized placebo controlled trial of vitamin D (vitamin D3 1000 IU/day vs. placebo) initiated during October through March (during fall and winter) in 8 to 14 year old African American and Caucasian children. The results of the trial will help establish the cutoff threshold value of serum 25(OH)D for defining vitamin D insufficiency in preadolescent and adolescent children. Safety of vitamin D supplementation will be assessed by measuring serum calcium at 0, 2 and 6 months and by monitoring for adverse events. Currently recommended adequate intake for vitamin D of 200 IU daily may not meet the body's daily needs for vitamin D. Therefore, it is likely that a higher level of daily vitamin D intake may be needed to meet the body's skeletal and non-skeletal demands for vitamin D. Determining the dietary required intake of vitamin D for the prevention of vitamin D insufficiency during childhood has immense public health potential for addressing health disparities and ensuring better bone health during adulthood. The primary outcome measure will be serum 25(OH)D and parathyroid hormone (PTH). The secondary outcome measures will include: markers of bone formation (serum P1NP) and bone resorption (serum CTX).We will also examine differences in serum 25(OH)D, PTH, and markers of bone turnover in African American vs. Caucasian children.

Detailed description

Epidemiologic and clinical data document a high prevalence of vitamin D insufficiency among adults and adolescents in the US. Vitamin D insufficiency during childhood has the potential to impact the acquisition of peak bone mass. Vitamin D insufficiency is also associated with several non-skeletal disorders including cancer (prostate, breast, and colon), diabetes mellitus (type 1 and type 2), and multiple sclerosis. In our pilot study nearly 50% of 6 to 10 year old African American children residing in Pittsburgh, Pennsylvania, were deemed vitamin D insufficient (serum 25-hydroxyvitamin D (25(OH)D): ≤ 20 ng/mL; Rajakumar K, et al. Clinical Pediatrics. 2005;44:683-692). To extend this field further, we are proposing a randomized placebo-controlled trial of vitamin D3 for establishing the serum 25-hydroxyvitamin D (25(OH)D) cutoff threshold levels for defining vitamin D insufficiency during childhood and to document the safety and efficacy of treatment on the vitamin D status of the study cohort. A total of 168 (African American: 84, Caucasian: 84) 8 to 14 year old preadolescent and adolescent children will undergo a randomized-placebo controlled trial (RCT) of vitamin D3 1000 IU daily vs. placebo for 6 months initiated during fall and winter (October through March). Safety of vitamin D supplementation will be assessed by measuring serum calcium at 0, 2 and 6 months and by monitoring for adverse events. We will also examine the differences in serum 25(OH)D, PTH, and markers of bone turnover in African American vs. Caucasian children. The primary outcome measure will be serum 25(OH)D and PTH. The secondary outcome measures will include: markers of bone formation: serum osteocalcin (OC) and bone resorption: serum C-terminal cross-linking telopeptide of type 1 collagen (serum CTX). Additional outcomes will include: dietary intake of vitamin D and calcium, skin color (Fitzpatrick Sunreactive Skin Type and Melanin Index), sun exposure, and body mass index. Vitamin D deficiency will be defined as serum 25-hydroxyvitamin D concentrations \<20 ng/mL. Public health importance of childhood vitamin D insufficiency is linked to the impact of vitamin D status on the acquisition of peak bone mass. Reduced peak bone mass can predispose to premature onset of osteoporosis and increase the risk for osteoporosis related fragility fractures. Achieving and maintaining vitamin D sufficiency during childhood can positively impact the skeletal health of children and reduce their osteoporosis burden during adulthood, and modify their risk for the non-skeletal disorders associated with chronic vitamin D insufficiency. Paucity of data regarding threshold levels of serum 25(OH)D associated with vitamin D insufficiency status among school age children and the likelihood that the serum 25(OH)D threshold levels for vitamin D sufficiency could be different among African American and Caucasian children makes it compelling for this issue to be explored. Based on expert opinion and supportive data in the medical literature, we feel that the currently recommended adequate intake for vitamin D for pre- and adolescent children (200 IU daily) is woefully inadequate to meet the daily needs for vitamin D. Therefore, it is likely that a higher level of daily vitamin D intake may be needed to meet the body's skeletal and non-skeletal demands for vitamin D. This study will determine the serum 25(OH)D cutoff for the definition of vitamin D insufficiency and document the safety and efficacy of treatment on vitamin D status.

Interventions

DIETARY_SUPPLEMENTVitamin D3 1000 IU

Vitamin D3 1000 IU Tablet once daily for 6 months

DIETARY_SUPPLEMENTPlacebo Tablet

Placebo Tablet once daily for 6 months

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
8 Years to 14 Years
Healthy volunteers
Yes

Inclusion criteria

* Age: 8-14 years * Race: African American or Caucasian * Children not taking multivitamins for at least 1 month before enrollment and agree not to start any multivitamin supplements during the 6-month trial period. * Children who are on multivitamins can be considered for enrollment only if they are able to and agree to stop their multivitamin tablet for a 1 month washout period prior to enrollment. * Absence of chronic diseases that could affect growth or calcium or vitamin D metabolism

Exclusion criteria

* Hepatic or renal disease * Metabolic rickets * Malabsorptive disorders (Crohn's disease, cystic fibrosis and celiac disease) or cancer * Treatment with anticonvulsants or systemic glucocorticoids

Design outcomes

Primary

MeasureTime frameDescription
Serum 25-hydroxyvitamin D6 monthsCirculating concentration of 25 hydroxyvitamin D is a biomarker of vitamin D status. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D concentrations \<20 ng/mL.

Secondary

MeasureTime frameDescription
Parathyroid Hormone (PTH) Dietary Data6 months
Osteocalcin (OC)6 monthsMarker of bone formation
Collagen Type 1 Cross-linked C-telopeptide (CTx)6 monthsCollagen type 1 cross-linked C-telopeptide (CTx) is a marker of bone resorption.

Countries

United States

Participant flow

Recruitment details

We enrolled healthy 8- to 14-year-old children from October through March of 2008 through 2011.

Pre-assignment details

Children receiving vitamin preparations underwent a 1-month washout before enrollment. Of 355 children assessed for eligibility, 304 were deemed eligible and among these 157 agreed to participate.

Participants by arm

ArmCount
Vitamin D3 Group
Vitamin D3 1000 IU Tablet Vitamin D3 1000 IU: Vitamin D3 1000 IU Tablet once daily for 6 months
78
Placebo Group
Placebo Tablet Placebo Tablet: Placebo Tablet once daily for 6 months
79
Total157

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up816

Baseline characteristics

CharacteristicVitamin D3 GroupPlacebo GroupTotal
Age, Continuous11.2 years
STANDARD_DEVIATION 1.9
11.4 years
STANDARD_DEVIATION 2
11.3 years
STANDARD_DEVIATION 1.95
Body Mass Index21.6 kilograms/meters^2
STANDARD_DEVIATION 5.5
21.6 kilograms/meters^2
STANDARD_DEVIATION 6.2
21.6 kilograms/meters^2
STANDARD_DEVIATION 5.85
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
68 Participants63 Participants131 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
9 Participants15 Participants24 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
42 Participants42 Participants84 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
36 Participants37 Participants73 Participants
Region of Enrollment
United States
78 participants79 participants157 participants
Sex: Female, Male
Female
45 Participants34 Participants79 Participants
Sex: Female, Male
Male
33 Participants45 Participants78 Participants
Skin Type
I (easy burn, no tan)
4 participants6 participants10 participants
Skin Type
II (easy burn, slight tan)
14 participants13 participants27 participants
Skin Type
III (burn, then tan)
15 participants16 participants31 participants
Skin Type
IV (no burn, good tan)
36 participants27 participants63 participants
Skin Type
Unknown
2 participants1 participants3 participants
Skin Type
V (never burn, marked tan)
7 participants16 participants23 participants
Vitamin D-deficient: Defined as serum 25(OH)D <20 ng/mL
25(OH)D<20 ng/mL
42 participants45 participants87 participants
Vitamin D-deficient: Defined as serum 25(OH)D <20 ng/mL
25(OH)D>20 ng/mL
36 participants34 participants70 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 780 / 79
serious
Total, serious adverse events
0 / 780 / 79

Outcome results

Primary

Serum 25-hydroxyvitamin D

Circulating concentration of 25 hydroxyvitamin D is a biomarker of vitamin D status. Vitamin D deficiency was defined as serum 25-hydroxyvitamin D concentrations \<20 ng/mL.

Time frame: 6 months

Population: Intention to treat -- participants analyzed based on the group to which they were randomized but only included in the analysis if they had follow up data at 6 months.

ArmMeasureValue (MEAN)Dispersion
Vitamin D3 GroupSerum 25-hydroxyvitamin D26.7 ng/mLStandard Deviation 7.6
Placebo GroupSerum 25-hydroxyvitamin D22.4 ng/mLStandard Deviation 7.3
p-value: 0.003ANCOVA
Secondary

Collagen Type 1 Cross-linked C-telopeptide (CTx)

Collagen type 1 cross-linked C-telopeptide (CTx) is a marker of bone resorption.

Time frame: 6 months

Population: Intention to treat with participants analyzed by the group to which they were assigned but only analyzing participants with 6 month CTx data.

ArmMeasureValue (MEAN)Dispersion
Vitamin D3 GroupCollagen Type 1 Cross-linked C-telopeptide (CTx)1.4 ng/mLStandard Deviation 0.9
Placebo GroupCollagen Type 1 Cross-linked C-telopeptide (CTx)1.6 ng/mLStandard Deviation 0.9
p-value: 0.35t-test, 2 sided
Secondary

Osteocalcin (OC)

Marker of bone formation

Time frame: 6 months

Population: Intention to treat with participants analyzed in the group to which they were assigned but only using participants with 6 month OC data available.

ArmMeasureValue (MEAN)Dispersion
Vitamin D3 GroupOsteocalcin (OC)101.1 ng/mLStandard Deviation 48.3
Placebo GroupOsteocalcin (OC)104.8 ng/mLStandard Deviation 48.7
p-value: 0.66t-test, 2 sided
Secondary

Parathyroid Hormone (PTH) Dietary Data

Time frame: 6 months

Population: Intention to treat with participants analyzed by the group to which they were assigned but only analyzing those participants with follow up data for PTH at 6 months.

ArmMeasureValue (MEAN)Dispersion
Vitamin D3 GroupParathyroid Hormone (PTH) Dietary Data35.5 pg/mLStandard Deviation 16.3
Placebo GroupParathyroid Hormone (PTH) Dietary Data33.5 pg/mLStandard Deviation 17
p-value: 0.51t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026